Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001883850-24-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-04 | 2024-01-02+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,750 | 23.1K | +8% | +$663.2K |
| DM | 2024-01-04 | 2024-01-02+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $903.20 | -1,109 | 22.0K | -5% | -$1.00M |
| DM | 2024-01-04 | 2024-01-02+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,750 | 17.1K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | M | A | 650 | $378.98 | 22,457 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-03 | F | D | 688 | $912.30 | 22,448 | D | — | — | |
| 3 | Common | Common Stock | 2024-01-03 | M | A | 1,100 | $378.98 | 23,136 | D | — | — | |
| 4 | Common | Common Stock | 2024-01-02 | F | D | 421 | $888.34 | 22,036 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-03 | M | D | 1,100 | $0.00 | 15,987 | D | $378.98 · — to 2027-12-12 | 1,100 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-02 | M | D | 650 | $0.00 | 17,087 | D | $378.98 · — to 2027-12-12 | 650 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |